BTIG Reiterates Buy on Theravance Biopharma, Maintains $21 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.4%

Neg 0% Neu 89.4% Pos 0%

BTIG analyst Julian Harrison reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $21 price target.

Comments

No comments yet. Be the first!